Cas:160848-22-6 [6,6]-Phenyl C61 butyric acid methyl ester manufacturer & supplier

We serve Chemical Name:[6,6]-Phenyl C61 butyric acid methyl ester CAS:160848-22-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

[6,6]-Phenyl C61 butyric acid methyl ester

Chemical Name:[6,6]-Phenyl C61 butyric acid methyl ester
CAS.NO:160848-22-6
Synonyms:[6,6]-Phenyl-C61-butyric Acid Methyl Ester;[60]PCBM;MFCD07784544;Methyl [6,6]-Phenyl-C61-butyrate
Molecular Formula:C72H14O2
Molecular Weight:910.880
HS Code:29163990

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:2.6±0.1 g/cm3
Index of Refraction:3.362
PSA:26.30000
Exact Mass:910.099365
LogP:12.42

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like [6,6]-Phenyl-C61-butyric Acid Methyl Ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Methyl [6,6]-Phenyl-C61-butyrate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[6,6]-Phenyl-C61-butyric Acid Methyl Ester Use and application,[60]PCBM technical grade,usp/ep/jp grade.


Related News: Symonds’ board has backed Walmsley’s leadership. In response to Elliott’s open attack earlier this month, the GSK board said it “strongly believes” Walmsley is the “right leader” for the company, citing “widespread and strong support” from GSK’s largest shareholders for Walmsley’s newly unveiled plan to improve the company’s performance. 1-(2-phenyl-[1,3]dithian-2-yl)-propan-2-one manufacturers Except current data is insufficient to determine its benefit in patients who are negative for anti-AChR antibodies. 2-phenyl-benzo[1,3]oxathiole suppliers Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “The data being presented at EULAR add to the growing body of evidence for anifrolumab that demonstrate a compelling clinical profile with the potential to address significant unmet medical needs in this debilitating disease. ethyl 3-hydroxy-3-methyl-7-phenyl-4-heptenoate vendor & factory.